These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 33416680)

  • 1. An Innovative Model for Implementing Office-Based Opioid Treatment in Community-Based Settings.
    Brooks EM; Brasler P
    J Health Care Poor Underserved; 2020; 31(3):1054-1060. PubMed ID: 33416680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers.
    LaBelle CT; Han SC; Bergeron A; Samet JH
    J Subst Abuse Treat; 2016 Jan; 60():6-13. PubMed ID: 26233698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 4. Training in office-based opioid treatment with buprenorphine in US residency programs: A national survey of residency program directors.
    Tesema L; Marshall J; Hathaway R; Pham C; Clarke C; Bergeron G; Yeh J; Soliman M; McCormick D
    Subst Abus; 2018; 39(4):434-440. PubMed ID: 29513136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term retention in Office Based Opioid Treatment with buprenorphine.
    Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
    J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary care and medication management characteristics among patients receiving office-based opioid treatment with buprenorphine.
    Du CX; Shi J; Tetrault JM; Madden LM; Barry DT
    Fam Pract; 2022 Mar; 39(2):234-240. PubMed ID: 34893825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychoactive medications and disengagement from office based opioid treatment (obot) with buprenorphine.
    Weinstein ZM; Cheng DM; Quinn E; Hui D; Kim H; Gryczynski G; Samet JH
    Drug Alcohol Depend; 2017 Jan; 170():9-16. PubMed ID: 27865152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Responding to the opioid and overdose crisis with innovative services: The recovery community center office-based opioid treatment (RCC-OBOT) model.
    Ashford RD; Brown AM; McDaniel J; Neasbitt J; Sobora C; Riley R; Weinstein L; Laxton A; Kunzelman J; Kampman K; Curtis B
    Addict Behav; 2019 Nov; 98():106031. PubMed ID: 31326776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementing Office-Based Opioid Treatment Models in Primary Care.
    Brooks EM; Tong S
    J Am Board Fam Med; 2020; 33(4):512-520. PubMed ID: 32675262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Financial sustainability of payment models for office-based opioid treatment in outpatient clinics.
    Hodgkin D; Horgan C; Bart G
    Addict Sci Clin Pract; 2021 Jul; 16(1):45. PubMed ID: 34225785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Very early disengagement and subsequent re-engagement in primary care Office Based Opioid Treatment (OBOT) with buprenorphine.
    Hui D; Weinstein ZM; Cheng DM; Quinn E; Kim H; Labelle C; Samet JH
    J Subst Abuse Treat; 2017 Aug; 79():12-19. PubMed ID: 28673522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication-assisted therapy for opioid-dependent incarcerated populations in New Mexico: statewide efforts to increase access.
    Trigg BG; Dickman SL
    Subst Abus; 2012; 33(1):76-84. PubMed ID: 22263716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Training in Buprenorphine and Office-Based Opioid Treatment: A Survey of Psychiatry Residency Training Programs.
    Suzuki J; Ellison TV; Connery HS; Surber C; Renner JA
    Acad Psychiatry; 2016 Jun; 40(3):498-502. PubMed ID: 26017618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Timing of hepatitis C treatment initiation and retention in office-based opioid treatment with buprenorphine: a retrospective cohort study.
    Geist ML; Radick AC; Tsui JI; Blalock KL; Adwell A; Tamru E; Connolly NC; James JR
    Addict Sci Clin Pract; 2023 May; 18(1):33. PubMed ID: 37231486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 and practice transformation: Building an office-based opioid treatment program in a family medicine residency practice.
    Colistra AL; Chung YK; Harbove S; Taveras YJ; Letcher A; Biery N; Keister DM
    Fam Syst Health; 2023 Jun; 41(2):235-239. PubMed ID: 36548043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Common elements in opioid use disorder guidelines for buprenorphine prescribing.
    Atkinson TJ; Pisansky AJB; Miller KL; Yong RJ
    Am J Manag Care; 2019 Mar; 25(3):e88-e97. PubMed ID: 30875177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Group-based treatment of opioid use disorder with buprenorphine: A systematic review.
    Sokol R; LaVertu AE; Morrill D; Albanese C; Schuman-Olivier Z
    J Subst Abuse Treat; 2018 Jan; 84():78-87. PubMed ID: 29195596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlling the Swing of the Opioid Pendulum.
    Comerci G; Katzman J; Duhigg D
    N Engl J Med; 2018 Feb; 378(8):691-693. PubMed ID: 29466151
    [No Abstract]   [Full Text] [Related]  

  • 19. Office-Based Buprenorphine Treatment: Identifying Factors That Promote Retention in Opioid-Dependent Patients.
    Noe SR; Keller T
    J Addict Nurs; 2020; 31(1):23-29. PubMed ID: 32132421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medication-Assisted Treatment for Opioid Addiction in the United States: Critique and Commentary.
    McElrath K
    Subst Use Misuse; 2018 Jan; 53(2):334-343. PubMed ID: 28862903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.